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Background: Atypical antipsychotics have been found to be associated with
hyperuricemia. Risperidone, one of the atypical antipsychotics, might be related to
the hyperuricemia among autism spectrum disorder (ASD) patients. The aims of this
study were to determine the prevalence of hyperuricemia in ASD patients treated
with risperidone and to determine associations between serum uric acid levels and
risperidone dosage, treatment duration, and metabolic parameters.
Methods: 127 children and adolescents with ASD treated with risperidone and 76
age-matched risperidone-naïve patients with ASD were recruited. The clinical data
and laboratory data were analyzed. Hyperuricemia was defined as serum uric acid
>5.5 mg/dl.
Results: Hyperuricemia was present in 44.70% of risperidone-naïve patients with
ASD and 57.50% of ASD patients treated with risperidone. The fasting uric acid
levels were significantly higher in the risperidone group than in the risperidone-naïve
group (5.70 vs. 5.35 mg/dl, P = 0.01). The increased uric acid concentrations were
significantly associated with adolescent patients treated with risperidone. The higher
dose of risperidone and/or the longer treatment time were associated with the increased
uric acid levels. Uric acid levels significantly rose with body mass index (BMI), waist
circumference (WC), triglyceride (TG) levels, triglycerides to high-density lipoprotein
cholesterol ratio (TG/HDL-C), insulin levels, homeostatic model assessment index
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(HOMA-IR), high-sensitivity CRP (hs-CRP) levels, and leptin levels. Conversely, the
levels of HDL-C and adiponectin were negatively correlated with uric acid levels. In
multiple regression analysis, there were age, BMI, TG/HDL-C ratio, and adiponectin
levels remained significantly associated with uric acid levels.
Conclusion: Hyperuricemia may play a role in metabolic adverse effect in children and
adolescents with ASDs receiving the high dose and/or the long-term treatment with
risperidone.
Keywords: serum uric acid levels, risperidone, autism spectrum disorder, hyperuricemia, metabolic adverse
effects
INTRODUCTION
Uric acid is the final oxidation product of the purine
degradation in humans. Uric acid at normal plasma levels
acts as a free-radical scavenger, which contributes to the
neuroprotective effect. Studies, however, have demonstrated
that an excessive amount of uric acid is correlated with
the risk of cardiovascular disease (Hongo et al., 2010;
Trepiccione and Perna, 2015). Hyperuricemia has been
associated with abdominal obesity (Godin et al., 2015),
inflammation (Baldwin et al., 2011), type 2 diabetes (Dehghan
et al., 2008), dyslipidemia (Peng et al., 2015), and metabolic
syndrome (Sagodi et al., 2015). An excessive amount of
uric acid is considered to be a mediator of proinflammatory
endocrine imbalance in adipose tissue, contributing to the
development of dyslipidemia and low-grade inflammation
(Baldwin et al., 2011). Patients with autism spectrum disorder
(ASD) may have increased levels of uric acid (Page and
Coleman, 2000; Jinnah et al., 2013; Lindberg et al., 2015).
Mitochondrial and purinergic dysfunction have been associated
with mental illnesses such as bipolar disorder, ASD, and
schizophrenia (Lindberg et al., 2015). A previous study found
increased levels of serum uric acid in adolescent patients with
bipolar mania when treated with an atypical antipsychotic,
olanzapine (Tohen et al., 2007). and this may enhance
increased cardiovascular risk when using antipsychotics as
treatment.
Atypical antipsychotic agents are widely used
psychopharmacological interventions for autism spectrum
disorder (ASD). Among the atypical antipsychotic agents,
risperidone has demonstrated considerable benefits in
reducing several behavioral symptoms associated with
ASD. Previous studies reported that treatment with
olanzapine was associated with the increase in uric acid
concentrations (Tohen et al., 2007, 2008; Kryzhanovskaya
et al., 2009). There is, however, no report of the prevalence
of hyperuricemia in ASD patients treated with risperidone
and how risperidone affects the uric acid levels in ASD
patients.
The purposes of this study were to determine the prevalence
of hyperuricemia in ASD patients treated with risperidone and
to determine the association between serum uric acid levels
and risperidone dosage, treatment duration, and metabolic
parameters.
MATERIALS AND METHODS
Subjects and Study Design
Children and adolescent patients with ASD were recruited from
the Yuwaprasart Waithayopathum Child Psychiatric Hospital,
Samut Prakan, Thailand. One hundred and twenty seven
patients with ASD treated with risperidone made up the
case group. These patients were on risperidone more than
12 months prior to assessment. The control group was 76
risperidone-naïve patients with ASD, age-matched with patients
in the case group. Regarding the risperidone-treated group,
the recommended risperidone dosing for pediatric indications
from the U.S. Food and Drug Administration (FDA) was
adjusted according to weight; low dose, recommended dose,
and high dose. The recommended dose of risperidone is 0.25–
0.5 mg/day for patients with a body weight less than 20 kg
and 0.5–1 mg/day for patients with body weight equal to
or greater than 20 kg. Risperidone administration lower than
the FDA recommendation was classified as the low dose,
while risperidone dosage higher than FDA recommendation
was classified as the high dose. Patients were classified into
four groups based on the period of risperidone administration:
Group 1 (0–24 months), Group 2 (>24 to 60 months), Group
3 (>60 to108 months), and Group 4 (>108 months). The
nursing staff confirmed patient compliance. All the adolescent
patients of 3–20 years were diagnosed as ASD according to
the Diagnostic and Statistical Manual of Mental Disorders,
fourth edition. Risperidone-treated patients or risperidone-naïve
patients receiving concomitant drugs that could potentially affect
the level of uric acid or other metabolic parameters were
excluded from the study. Parents of all the patients involved
in the study gave informed written consent to participate. The
Ramathibodi Ethics Committee, Bangkok, Thailand, approved
this study. Anthropometric measurements and biomedical
parameters were recorded and analyzed in the risperidone-
treated group. Body mass index (BMI) was calculated as body
weight in kilograms divided by the height in meter squared
(kg/m2).
Serum Uric Acid and Biochemical
Parameters Measurement
Blood samples for the chemistry panel were collected in the
morning after overnight fasting. The samples were immediately
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TABLE 1 | Demographic and clinical characteristics of subjects.
Characteristics Naïve-Risperidone, n = 76 Risperidone, n = 127 P-value
Age-group 0.15b
Children, n (%) 42 (55.3%) 57 (44.9%)
Adolescents, n (%) 34 (44.7%) 70 (55.1%)
Gender, n (%)
Male 61 (80.3%) 113 (89.0%) 0.09b
Female 15 (19.7%) 14 (11.0%)
Uric acid levels (mg/dl) 5.35 (4.60–6.28) 5.70 (4.90–7.20) 0.01∗a
Hyperuricemia 0.08b
(Uric acid > 5.5 mg/dl), n (%) 34 (44.70%) 73 (57.50%)
(Uric acid ≤ 5.5 mg/dl), n (%) 42 (55.30%) 54 (42.50%)
Risperidone dose (mg/day) – 1.00 (0.50–1.50) –
Dose of risperidone treatment, n (%)
Low dose – 13 (10.24%) –
Recommended dose – 68 (53.54%)
High dose – 46 (36.22%)
Duration of treatment (months) – 61.27 (39.83–87.97) –
Duration of treatment, n (%)
0–24 months 6 (4.72%)
>24–60 months – 50 (39.37%) –
>60–108 months – 52 (40.95%)
>108 months – 19 (14.96%)
Medication regimen
Single risperidone – 48 (37.80%) –
Concomitant therapy – 79 (62.20%)
aStatistical significance was calculated by Mann–Whitney U Test.
bStatistical significance was calculated by Chi-squared test.
∗P-value < 0.05.
transferred to the central laboratory where they were analyzed.
Serum uric acid, glucose, and lipid profiles were determined by
the colorimetric method using automated equipment (FUJI DRI-
CHEM 4000i system, Germany). Hyperuricemia was defined as
the level of uric acid concentration in the blood >5.5 mg/dL
(Feig and Johnson, 2003). Insulin levels were measured by
enzyme-labeled chemiluminescent immunoassay in automated
equipment (IMMULITE R©2000 System-SIEMENS, Germany).
The homeostatic model assessment index (HOMA-IR) was
calculated using the formula: HOMA-IR = [fasting glucose
(mg/dl) × insulin (µIU/ml)]/405. The sandwich-ELISA assay in
automated equipment (BEP R© III System – SIEMENS, Germany)
measured leptin and adiponectin. Nephelometric technology
using automated equipment (Siemens BN ProSpec R© System,
SIEMENS, Germany) measured High sensitive C-reactive protein
(hs-CRP).
Statistical Analysis
Data were analyzed using SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA). Descriptive statistics were used to
describe the clinical characteristics of the subjects. Discrete
variables are expressed as counts (percentage) and continuous
variables as median with the interquartile range (Q1–Q3). The
nonparametric Mann–Whitney U test compared differences in
median values (interquartile range) between the two groups,
and Kruskal–Wallis test was used to make comparisons
between three groups. The Chi-squared test was used for
comparisons between two categorical variables. Accordingly,
for nonparametric data, the Spearman rank correlation test
measured relationships between two continuous random
variables. Stepwise multiple linear regression analysis was
used to adjust variables. Statistical significance was set at
P < 0.05.
RESULTS
The demographic and clinical characteristics of the patients were
summarized in Table 1. There was no significant difference
between the group of risperidone-naïve patients and risperidone-
treated patients in age and gender (P = 0.15 and P = 0.09).
In both groups, most of the patients were male. For the group
of risperidone-naïve patients, the serum uric acid levels were
5.35 mg/dl (IQR: 4.60–6.28) and 5.70 mg/dl (IQR: 4.90–7.20)
for the patients treated with risperidone. There were significant
differences between the groups in uric acid levels (P = 0.01,
Figure 1). Hyperuricemia was found in 34 (44.70%) patients from
the risperidone-naïve group and 73 (57.50%) subjects from the
risperidone group (Table 1).
In the risperidone group, the median risperidone dose of the
subjects was 1 mg/ day (IQR: 0.50–1.50). Sixty-eight (53.54%)
patients were treated with risperidone at the FDA-recommended
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FIGURE 1 | Comparison of uric acid levels between risperidone-naïve
patients with ASD (n = 76) and risperidone-treated patients with ASD
(n = 127). Statistical significance was calculated by Mann–Whitney U Test; ∗
P-value < 0.05.
dose. Forty-six (36.22%) of them have been provided with higher
than the FDA-recommended doses, while thirteen (10.24%)
patients received lower than the FDA-recommended dose. The
median duration of risperidone treatment was 61.27 months
(IQR: 39.83–87.97). Most patients received risperidone for
>60–108 months (>5–9 years) (Table 1). Forty-eight (37.80%)
received only risperidone, the remaining patients received
risperidone-containing concomitant therapy (62.20%). Median
uric acid levels were significantly higher in the adolescents than
in those children (6.80 mg/dl (IQR: 5.40–7.90) vs. 5.30 mg/dl
(IQR: 4.60–5.95), P < 0.0001), Figure 2A. The significant
associations between serum uric acid concentrations and the
dose of risperidone and the duration of risperidone treatment
were found. The results demonstrated that there were statistically
significant differences in uric acid levels between risperidone
dose groups: low dose, recommended dose, and high dose
(4.60 mg/dl (IQR: 4.20–5.95) vs. 5.75 mg/dl (IQR: 5.13–
7.35) vs. 5.95mg/dl (IQR: 5.08–7.30), P = 0.03), Figure 2C.
There were significant differences between treatment duration
groups: 0–24 months, >24–60 months, >60–108 months, and
>108 months (4.60 mg/dl (IQR: 4.45–6.28) vs. 5.25 mg/dl (IQR:
4.58–6.23) vs. 5.95 mg/dl (IQR: 5.40–7.58) vs. 7.60 mg/dl (mg/dl
5.70–8.40), P< 0.00001), Figure 2D. The levels of serum uric acid
were not significantly different between males and females in the
risperidone group (5.70 mg/dl (IQR: 4.95–7.25) vs. 6.10 mg/dl
(IQR: 4.48–7.23), P = 0.95), Figure 2B. The fasting uric acid
concentrations were not associated with the gender. There were
no differences of serum uric acid levels between the exclusive
risperidone group and the co-medication groups (5.70 mg/dl
(IQR: 4.60–7.05) vs. 5.80 mg/dl (IQR: 5.20–7.30), P = 0.89),
Figure 2E.
Table 2 shows the correlation between uric acid level and
continuous variables of anthropometric, clinical, and biomedical
parameters. Serum uric acid levels were positively correlated with
age (rs = 0.53, P < 0.0001) and risperidone dose (rs = 0.23,
P = 0.01) and duration of treatment (rs = 0.43, P < 0.0001).
Also, our study found significant positive correlations between
serum uric acid level and BMI (rs = 0.62, P < 0.0001), waist
circumference (WC) (rs = 0.27, P = 0.003), triglyceride (TG)
levels (rs = 0.36, P< 0.0001), TG/HDL-C (rs = 0.47, P< 0.0001),
insulin levels (rs = 0.19, P = 0.04), HOMA-IR (rs = 0.20,
P = 0.03), leptin levels (rs = 0.50, P < 0.0001), and hs-
CRP levels (rs = 0.37, P < 0.0001). There were significant
negative correlations between serum uric acid levels and HDL
cholesterol levels (rs = –0.37, P < 0.0001) and adiponectin
levels (rs = –0.67, P < 0.0001). Serum uric acid levels did not
correlate with LDL cholesterol levels (rs = –0.18, P = 0.05),
and glucose levels (rs = –0.03, P = 0.75), Table 2. Multiple
linear regression analysis indicated that age (P = 0.003), BMI
(P = 0.021), TG/HDL-C (P = 0.030) and adiponectin levels
(P = 0.001) were significantly correlated with serum uric acid
levels, Table 3.
DISCUSSION
The present study is the first study on the prevalence of
hyperuricemia in ASDs patients, and it is the first study on
the impact of serum uric acid on metabolic adverse effect
in ASDs children and adolescents treated with risperidone.
The increased uric acid concentrations were significantly
associated with adolescent patients treated with risperidone,
which is concordance with the previous study in the pediatric
population (Cardoso et al., 2013). The levels of uric acid were
significantly higher in the risperidone treatment group than
in the risperidone-naïve group (5.70 mg/dl vs. 5.35 mg/dl,
P = 0.01). However, the levels of uric acid in the risperidone-
naïve group were higher than in the normal children and
adolescent group (Cardoso et al., 2013) (5.35 mg/dl vs.
4.19 mg/dl). The frequencies of hyperuricemia (>5.5 mg/dl)
were differences among the risperidone group, the risperidone-
naïve group, and the normal children and adolescent group
(Cardoso et al., 2013) (57.50% vs. 44.70% vs. 12.40%). Many
studies demonstrated that treatment with olanzapine was
associated with the increase in uric acid concentrations (Tohen
et al., 2007, 2008; Kryzhanovskaya et al., 2009). In this
study, it was found that the treatment with risperidone was
associated with increased levels of uric acid. A higher dose
of risperidone and/or a longer treatment time are associated
with higher levels of serum uric acid. However, the previous
studies reported that Mitochondrial and purinergic dysfunction
have been associated with ASD (Frye, 2015; Lindberg et al.,
2015). As shown by Chauhan et al. (2011), the frontal lobe,
cerebellum, and temporal lobe in post-mortem brains of
children with autism had diminished expression of mitochondrial
electron transport chain proteins. Page and Coleman found
the de novo purine synthesis is increased 3–4-fold in the
hyperuricosuric autistic patients compared to normal controls
(Page and Coleman, 2000). Therefore, the altered uric acid
concentrations in patients with ASD may be the result of the
disease itself. The treatment with antipsychotics may be directly
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FIGURE 2 | Associations between uric acid levels and (A) age-group (B) gender (C) dose of risperidone treatment (D) duration of risperidone treatment, and (E)
medication regimen in risperidone-treated patients with ASD (n = 127) a, Statistical significance was calculated by Mann–Whitney U Test; b, Statistical significance
was calculated by Kruskal–Wallis test ∗P-value < 0.05.
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TABLE 2 | Correlations between uric acid levels and continuous variables of anthropometric, clinical, and biomedical parameters in risperidone-treated
patients with ASD (n = 127).
Variables Variables; Median(IQR) Uric acid levels (mg/dl)
Correlation coefficient(rs) (n = 127) P-value
Age (years) 10.20 (8.60–13.80) 0.53 <0.0001∗
Risperidone dose (mg/day) 1.00 (0.50–1.50) 0.23 0.01∗
Treatment duration (months) 61.27 (39.83–87.97) 0.43 <0.0001∗
BMI 19.20 (15.71–24.86) 0.62 <0.0001∗
Waist circumference (cm) 70.00 (56.50–84.00) 0.27 0.003∗
LDL cholesterol (mg/dl) 106.00 (86.00–125.00) −0.18 0.05
Triglyceride (mg/dl) 76.00 (59.00–111.00) 0.36 <0.0001∗
HDL cholesterol (mg/dl) 51.00 (43.00–64.00) −0.37 <0.0001∗
TG/HDL-C 1.48 (1.02–2.28) 0.47 <0.0001∗
Glucose (mg/dl) 85.00 (82.00–91.00) −0.03 0.75
Insulin (µIU/ml) 5.59 (2.31–10.28) 0.19 0.04∗
HOMA−IR 1.24 (0.49–2.16) 0.20 0.03∗
hs-CRP (mg/l) 0.70 (0.17–2.30) 0.37 <0.0001∗
Leptin (ng/ml) 4.17 (1.58–12.18) 0.50 <0.0001∗
Adiponectin (ng/ml) 31.00 (18.00–44.85) −0.67 <0.0001∗
Statistical significance was calculated by Spearman’s correlation test.
∗P-value < 0.05.
or secondarily the result of the adverse treatment-induced
hyperuricemia.
Hyperuricemia is associated with the increased risk of
cardiovascular disease. Increased blood uric acid concentrations
are correlated with obesity (Godin et al., 2015), inflammation
(Baldwin et al., 2011), type 2 diabetes (Dehghan et al., 2008),
dyslipidemia (Peng et al., 2015; Stelmach et al., 2015), and
the metabolic syndrome (Sagodi et al., 2015). In this study,
correlations with obesity were found. BMI was positively
correlated with serum uric acid levels, consistent with the results
in Chinese (Zhang et al., 2014) and Taiwanese (Lu et al., 2008)
pediatric populations. Ford et al. (2007) found hyperuricemia
related to BMI and dyslipidemia in US children and adolescents.
Stelmach et al. (2015) reported results similar to the present study
showing that increased serum uric acid levels were correlated
with increased serum TG levels and increased TG/HDL-C
ratios and decreased HDL-C levels. Multiple regression analysis
confirmed the significant positive correlation between serum
TABLE 3 | Multiple linear regression analysis of serum uric acid levels in
risperidone-treated patients with ASD (n = 127).
Variables Beta SE P-value
Age (years) 0.264 0.035 0.003∗
BMI 0.238 0.028 0.021∗
TG/HDL-C 0.179 0.131 0.030∗
Adiponectin (ng/ml) −0.302 0.008 0.001∗
Variables entered on method: age, risperidone dose, treatment duration, BMI,
WC, LDL-C, TG, HDL-C, TG/HDL, glucose, insulin, HOMA-IR, hs-CRP, leptin, and
adiponectin.
R2 = 0.539, Adjusted R2 = 0.518, P < 0.0001
Statistical significance was calculated by Stepwise method.
∗P-value < 0.05.
uric acid and TG/HDL ratio. There is an explanation for
the relationship between uric acid and TG in that the fatty
acids synthesis in the liver is associated with the de novo
synthesis of purines, consequently accelerating the production
of uric acid (Matsuura et al., 1998). Previous reports indicated
that the increased TG/HDL ratio is one of the predictors of
cardiovascular disease (Marotta et al., 2010; Giannini et al.,
2011).
Insulin resistance seems to associate with hyperuricemia.
The present study found that insulin level and HOMA-
IR correlated positively with serum uric acid level, which
is consistent with previous studies (Gill et al., 2013; de
Miranda et al., 2015). Insulin resistance probably contributes
hyperuricemia through either lower renal excretion, higher
synthesis or both (de Oliveira and Burini, 2012). Thus, people
with normal glycemia may have excessive uric acid levels if
they are insulin resistant. Excessive production of uric acid
may result in impaired endothelial function (Choi et al., 2014).
In this study, it was shown that increased levels of uric
acid were correlated with the elevation of hs-CRP, which is
consistent with a previous study (Wasilewska et al., 2012). The
hs-CRP is an essential indicator of atherosclerosis (Kamath
et al., 2015) and the findings lead to the proposal that
serum uric acid might be a relevant marker for cardiovascular
disease.
The action of adipokines is related to uric acid concentrations
as well. Increased leptin levels were associated with elevated
uric acid levels (de Oliveira and Burini, 2012), and leptin might
be a useful marker of the metabolic syndrome in adolescents
(Gonzaga et al., 2014). The present study found that serum uric
acid levels linearly increased with increased serum leptin levels,
which is consistent with the previous report (Fruehwald-Schultes
et al., 1999). It was suggested that uric acid may serve as a
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biomarker of metabolic syndrome. The earlier study showed that
uric acid amplifies oxidative stress in adipocytes by decreasing
adiponectin (Baldwin et al., 2011). This pro-oxidative action
may accelerate adipose formation (Lee et al., 2009; Johnson
et al., 2011) and contribute to insulin resistance (Furukawa
et al., 2004). The study from Tamba et al. (2008) reported that
increased serum uric acid levels correlated with decreased serum
adiponectin levels, which is consistent with this study. Multiple
regression analysis confirmed the significant inverse correlation
between serum uric acid levels and adiponectin levels. Decreased
plasma adiponectin levels are closely related to obesity-related
diseases such as dyslipidemia, type 2 DM and cardiovascular
disease.
Limitation of this study includes that the data analysis was
restricted due to the cross-sectional design of the study. To
confirm the risperidone effect on serum uric acid levels in the
patients with ASD, a longitudinal prospective study is necessary.
CONCLUSION
In summary, the increased uric acid concentrations were
associated with adolescent patients treated with risperidone.
Fasting uric acid levels were significantly higher in ASD
patients treated with risperidone than in the risperidone-
naïve patients. The higher dose of risperidone and/or the
longer treatment time were associated with the increased
uric acid levels. The treatment with antipsychotics may
be directly or secondarily the result of the adverse
treatment-induced hyperuricemia in ASD patients. Our
findings indicate that hyperuricemia is associated with
metabolic adverse effects. Clinicians should be aware of
the possible consequences of hyperuricemia in children and
adolescents with autism spectrum disorder treated with
risperidone.
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